PL351500A1 - Use of cytidine derivatives for the treatment of leukaemia - Google Patents
Use of cytidine derivatives for the treatment of leukaemiaInfo
- Publication number
- PL351500A1 PL351500A1 PL00351500A PL35150000A PL351500A1 PL 351500 A1 PL351500 A1 PL 351500A1 PL 00351500 A PL00351500 A PL 00351500A PL 35150000 A PL35150000 A PL 35150000A PL 351500 A1 PL351500 A1 PL 351500A1
- Authority
- PL
- Poland
- Prior art keywords
- group
- leukaemia
- treatment
- alkynyl
- alkenyl
- Prior art date
Links
- 208000032839 leukemia Diseases 0.000 title abstract 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 title 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 229940104302 cytosine Drugs 0.000 abstract 1
- 239000001177 diphosphate Chemical group 0.000 abstract 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical group [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 abstract 1
- 235000011180 diphosphates Nutrition 0.000 abstract 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical group NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 abstract 1
- 229960004413 flucytosine Drugs 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 150000004712 monophosphates Chemical group 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 239000001226 triphosphate Chemical group 0.000 abstract 1
- 235000011178 triphosphate Nutrition 0.000 abstract 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical group OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/202—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/32—Thymopoietins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0644—Platelets; Megakaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/03—Compounds acting on the NO pathway, e.g. nitrososarginine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12673499P | 1999-03-29 | 1999-03-29 | |
| US12681399P | 1999-03-30 | 1999-03-30 | |
| PCT/CA2000/000334 WO2000057861A2 (en) | 1999-03-29 | 2000-03-28 | Use of cytidine derivatives for the treatment of leukaemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL351500A1 true PL351500A1 (en) | 2003-04-22 |
Family
ID=26824972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL00351500A PL351500A1 (en) | 1999-03-29 | 2000-03-28 | Use of cytidine derivatives for the treatment of leukaemia |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US6630480B1 (enExample) |
| EP (2) | EP1165096B1 (enExample) |
| JP (1) | JP2002540142A (enExample) |
| KR (2) | KR20020000554A (enExample) |
| CN (1) | CN1297281C (enExample) |
| AT (1) | ATE442151T1 (enExample) |
| AU (1) | AU773437C (enExample) |
| BR (1) | BR0009378A (enExample) |
| CA (1) | CA2366012A1 (enExample) |
| CZ (1) | CZ20013483A3 (enExample) |
| DE (1) | DE60042921D1 (enExample) |
| DK (1) | DK1165096T3 (enExample) |
| ES (1) | ES2333399T3 (enExample) |
| HK (1) | HK1041828B (enExample) |
| HU (1) | HUP0201708A3 (enExample) |
| IL (3) | IL145634A0 (enExample) |
| IS (1) | IS6086A (enExample) |
| MX (1) | MXPA01009888A (enExample) |
| NO (1) | NO323840B1 (enExample) |
| NZ (1) | NZ529882A (enExample) |
| PL (1) | PL351500A1 (enExample) |
| SK (1) | SK13822001A3 (enExample) |
| WO (1) | WO2000057861A2 (enExample) |
| ZA (1) | ZA200107963B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8114850B2 (en) | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| US7960540B2 (en) | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| US20110178161A1 (en) * | 1999-04-08 | 2011-07-21 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| PT1181304E (pt) | 1999-04-08 | 2008-01-23 | Antisoma Res Ltd | Actividade antiproliferativa de oligonucleótidos ricos em g e método de utilização dos mesmos para ligação a nucleolina |
| WO2001022950A2 (en) | 1999-09-24 | 2001-04-05 | Shire Biochem Inc. | Diosolane nucleoside analogs for the treatment or prevention of viral infection |
| CA2389745C (en) | 1999-11-04 | 2010-03-23 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| CN100376570C (zh) * | 2000-10-13 | 2008-03-26 | 希拉生物化学股份有限公司 | 改善胞间传输的二氧戊环类似物 |
| ATE450265T1 (de) * | 2001-03-23 | 2009-12-15 | Shire Canada Inc | Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält |
| AU2002242561A1 (en) * | 2001-03-30 | 2002-10-15 | Shire Biochem Inc. | Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine |
| US7158517B2 (en) | 2001-05-21 | 2007-01-02 | Intel Corporation | Method and apparatus for frame-based protocol processing |
| CA2465682A1 (en) * | 2001-11-02 | 2003-05-08 | Shire Biochem Inc. | Methods of treating leukemia |
| US20040192652A1 (en) * | 2002-12-06 | 2004-09-30 | Giles Francis J. | Pharmaceutical combinations and methods for the treatment of leukemia |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US20040248915A1 (en) * | 2003-04-25 | 2004-12-09 | Jacques Jolivet | Method for administration of troxacitabine |
| WO2005048925A2 (en) | 2003-11-14 | 2005-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds |
| KR100708016B1 (ko) * | 2004-01-20 | 2007-04-16 | 한국쓰리엠 주식회사 | 스탠드의 전후좌우 회전장치 |
| EP1804816B1 (en) * | 2004-03-26 | 2011-12-21 | Vion Pharmaceuticals, Inc. | Combination therapy comprising cloretazine(tm) |
| WO2007089646A1 (en) * | 2006-01-31 | 2007-08-09 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
| WO2007126871A1 (en) | 2006-03-29 | 2007-11-08 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
| US9262697B2 (en) * | 2006-09-25 | 2016-02-16 | Cambridge Research & Instrumentation, Inc. | Sample imaging and classification |
| EP3011961B1 (en) * | 2006-12-21 | 2020-11-11 | Biokine Therapeutics LTD. | 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation |
| US20110129550A1 (en) * | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
| CN105748465A (zh) | 2007-07-25 | 2016-07-13 | 卫材R&D管理株式会社 | 用于治疗癌症的多激酶抑制剂 |
| KR101530402B1 (ko) * | 2007-10-09 | 2015-06-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 급성 인간 골수성 백혈병 세포를 죽이는 트롬보포이에틴 수용체 효능제 (ｔｐｏｒａ) |
| US9427456B2 (en) | 2009-06-14 | 2016-08-30 | Biokine Therapeutics Ltd. | Peptide therapy for increasing platelet levels |
| WO2013160895A1 (en) | 2012-04-24 | 2013-10-31 | Biokine Therapeutics Ltd. | Peptides and use thereof in the treatment of large cell lung cancer |
| MX2017016844A (es) | 2015-07-16 | 2018-08-15 | Biokine Therapeutics Ltd | Composiciones y procedimientos para tratar cancer. |
| CA3014530A1 (en) | 2016-02-23 | 2017-08-31 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia |
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| WO2019245444A1 (en) | 2018-06-21 | 2019-12-26 | Medivir Ab | Base-modified cytidine nucleotides for leukemia therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6175008B1 (en) * | 1988-04-11 | 2001-01-16 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
| US5270315A (en) | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
| US5041449A (en) * | 1988-04-11 | 1991-08-20 | Iaf Biochem International, Inc. | 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections |
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US6350753B1 (en) * | 1988-04-11 | 2002-02-26 | Biochem Pharma Inc. | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
| NZ228645A (en) | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
| WO1990015104A2 (en) | 1989-06-05 | 1990-12-13 | Eastman Kodak Company | Impact resistant polymer blends |
| US5817667A (en) | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
| IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| US5643935A (en) * | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
| KR102127978B1 (ko) * | 2014-01-10 | 2020-06-29 | 삼성전자주식회사 | 구조도 생성 방법 및 장치 |
-
2000
- 2000-03-28 DE DE60042921T patent/DE60042921D1/de not_active Expired - Lifetime
- 2000-03-28 EP EP00913985A patent/EP1165096B1/en not_active Expired - Lifetime
- 2000-03-28 AU AU35466/00A patent/AU773437C/en not_active Ceased
- 2000-03-28 MX MXPA01009888A patent/MXPA01009888A/es active IP Right Grant
- 2000-03-28 HU HU0201708A patent/HUP0201708A3/hu unknown
- 2000-03-28 US US09/536,459 patent/US6630480B1/en not_active Expired - Lifetime
- 2000-03-28 WO PCT/CA2000/000334 patent/WO2000057861A2/en not_active Ceased
- 2000-03-28 KR KR1020017012514A patent/KR20020000554A/ko not_active Ceased
- 2000-03-28 SK SK1382-2001A patent/SK13822001A3/sk unknown
- 2000-03-28 NZ NZ529882A patent/NZ529882A/en not_active IP Right Cessation
- 2000-03-28 CA CA002366012A patent/CA2366012A1/en not_active Abandoned
- 2000-03-28 ES ES00913985T patent/ES2333399T3/es not_active Expired - Lifetime
- 2000-03-28 PL PL00351500A patent/PL351500A1/xx not_active Application Discontinuation
- 2000-03-28 BR BR0009378-5A patent/BR0009378A/pt not_active Application Discontinuation
- 2000-03-28 CN CNB008056692A patent/CN1297281C/zh not_active Expired - Fee Related
- 2000-03-28 HK HK02103744.1A patent/HK1041828B/en not_active IP Right Cessation
- 2000-03-28 AT AT00913985T patent/ATE442151T1/de not_active IP Right Cessation
- 2000-03-28 EP EP09169750A patent/EP2138179A1/en not_active Withdrawn
- 2000-03-28 IL IL14563400A patent/IL145634A0/xx active IP Right Grant
- 2000-03-28 KR KR10-2004-7021484A patent/KR20050005569A/ko not_active Ceased
- 2000-03-28 DK DK00913985.8T patent/DK1165096T3/da active
- 2000-03-28 JP JP2000607612A patent/JP2002540142A/ja active Pending
- 2000-03-28 CZ CZ20013483A patent/CZ20013483A3/cs unknown
-
2001
- 2001-09-25 IL IL145634A patent/IL145634A/en not_active IP Right Cessation
- 2001-09-26 IS IS6086A patent/IS6086A/is unknown
- 2001-09-27 ZA ZA200107963A patent/ZA200107963B/xx unknown
- 2001-09-28 NO NO20014727A patent/NO323840B1/no unknown
-
2002
- 2002-01-16 US US10/046,289 patent/US6747036B2/en not_active Expired - Lifetime
-
2004
- 2004-04-15 US US10/824,563 patent/US20040192654A1/en not_active Abandoned
-
2006
- 2006-02-07 IL IL173586A patent/IL173586A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1165096T3 (da) | Anvendelse af cytidinderivater til behandling af leukæmi | |
| AU674639B2 (en) | 3'-substituted nucleoside derivatives | |
| ATE369845T1 (de) | Behandlung der nebenwirkungen von statinen | |
| DE69929060D1 (de) | Beta-l-2'-deoxynukleoside für die behandlung von hepatitis b virus | |
| PL354784A1 (en) | Certain alkylene diamine-substituted heterocycles | |
| NZ330137A (en) | L-nucleoside and L-nucleotide derivatives and their use in treating a human infected with HBV or EBV | |
| ATE167679T1 (de) | Wirkstoffvorläufer von phosphonaten | |
| AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
| EP1631548A4 (en) | HEMMER OF ACT ACTIVITY | |
| EP1622616A4 (en) | HEMMER OF ACT ACTIVITY | |
| PL365285A1 (en) | Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs | |
| NZ223990A (en) | Acylated 2',3'-dideoxynucleosides and pharmaceutical compositions | |
| WO2000026225A3 (en) | Nucleosides with anti-hepatitis b virus activity | |
| WO2002078678A3 (en) | Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine | |
| EP0311068A3 (en) | Polyamine derivatives as antineoplastic agents | |
| EP1465616A4 (en) | TREATMENT OF SIDE EFFECTS OF STATINE USING URIDINE DERIVATIVES | |
| ES2173634T3 (es) | Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |